Fate Therapeutics (NASDAQ:FATE)‘s stock had its “buy” rating restated by equities researchers at Raymond James Financial in a report released on Tuesday.

A number of other research firms have also commented on FATE. HC Wainwright reiterated a “buy” rating on shares of Fate Therapeutics in a research report on Thursday, November 2nd. ValuEngine lowered Fate Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Zacks Investment Research lowered Fate Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, October 17th. BMO Capital Markets reiterated a “buy” rating and issued a $7.00 price target on shares of Fate Therapeutics in a research report on Thursday, November 2nd. Finally, Leerink Swann reiterated an “outperform” rating and issued a $7.00 price target on shares of Fate Therapeutics in a research report on Friday, September 8th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $6.79.

Shares of Fate Therapeutics (FATE) traded down $0.03 during mid-day trading on Tuesday, reaching $4.14. The company had a trading volume of 1,067,100 shares, compared to its average volume of 284,540. Fate Therapeutics has a twelve month low of $2.40 and a twelve month high of $5.68. The company has a debt-to-equity ratio of 0.32, a quick ratio of 7.21 and a current ratio of 7.21.

Fate Therapeutics (NASDAQ:FATE) last issued its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.01). The firm had revenue of $1.03 million for the quarter, compared to the consensus estimate of $0.95 million. Fate Therapeutics had a negative return on equity of 64.55% and a negative net margin of 935.09%. The business’s quarterly revenue was up .0% on a year-over-year basis. equities research analysts expect that Fate Therapeutics will post -0.99 EPS for the current fiscal year.

In other news, General Counsel Cindy Tahl sold 8,091 shares of the business’s stock in a transaction dated Monday, October 16th. The stock was sold at an average price of $3.85, for a total value of $31,150.35. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Daniel D. Shoemaker sold 13,225 shares of the business’s stock in a transaction dated Monday, October 16th. The shares were sold at an average price of $3.87, for a total value of $51,180.75. The disclosure for this sale can be found here. 10.88% of the stock is owned by insiders.

Several large investors have recently made changes to their positions in FATE. New York State Common Retirement Fund acquired a new position in shares of Fate Therapeutics in the 2nd quarter valued at about $131,000. Rhumbline Advisers acquired a new position in shares of Fate Therapeutics in the 2nd quarter valued at about $133,000. Hochman Cole Investment Advisors Inc. acquired a new position in Fate Therapeutics during the 3rd quarter worth approximately $158,000. Schwab Charles Investment Management Inc. acquired a new position in Fate Therapeutics during the 2nd quarter worth approximately $214,000. Finally, California State Teachers Retirement System acquired a new position in Fate Therapeutics during the 2nd quarter worth approximately $219,000. 60.97% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: This piece of content was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/12/12/fate-therapeutics-fate-buy-rating-reiterated-at-raymond-james-financial.html.

About Fate Therapeutics

Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.

Analyst Recommendations for Fate Therapeutics (NASDAQ:FATE)

Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.